In experimental colitis, systemic administration of specific iNOS inhibitor such as amino-guanidine or N-(3-(aminomethyl)benzyl) acetamidine results in amelioration of colitic symptoms, which further validates the pro-inflammatory effect of iNOS (86, 87). This evidence concerns the gene NOS2 and colitis.